Seth Lederman - 29 Jun 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TNXP
Reported as of: 29 Jun 2022
Net transaction value: +$34,200
SEC form: 4
Accepted by SEC: 01 Jul 2022, 16:05:23 UTC
Prior SEC filing: 28 Mar 2022
Next SEC filing: 24 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Seth Lederman

Key filing fact

Seth Lederman filed Form 4 for Tonix Pharmaceuticals Holding Corp. (TNXP) on 01 Jul 2022.

Key facts

This page summarizes Seth Lederman's Form 4 filing for Tonix Pharmaceuticals Holding Corp. (TNXP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2022, 16:05.

Change

Previous filing in this sequence was filed on 28 Mar 2022.
Current net transaction value: +$34,200.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNXP transaction

Common Stock, $0.001 par value

Purchase

Transaction value: $34,200
Shares: +20,000
Change %: +472%
Price: $1.71
Shares after: 24,235
Date: 29 Jun 2022
Ownership: By IRA Account
Footnotes: F1

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,505
Date: 29 Jun 2022
Ownership: Direct
Footnotes: F1

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1
Date: 29 Jun 2022
Ownership: By spouse
Footnotes: F1

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1
Date: 29 Jun 2022
Ownership: By Leder Laboratories, Inc.
Footnotes: F1, F2

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1
Date: 29 Jun 2022
Ownership: By Starling Pharmaceuticals, Inc.
Footnotes: F1, F2

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7
Date: 29 Jun 2022
Ownership: By Lederman & Co., LLC
Footnotes: F1, F2

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2
Date: 29 Jun 2022
Ownership: By L&L Technologies, LLC
Footnotes: F1, F2

TNXP holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2
Date: 29 Jun 2022
Ownership: By Targent Pharmaceuticals, LLC
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares reported reflect a 1-for-32 reverse stock split effective May 17, 2022.

Footnote F2

Reporting person may be deemed to be a control person of this entity.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .